Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
Company Details
- Employees
- 175
- Founded
- -
- Address
- 601 Gateway Blvd, Suite 900,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://structuretx.com/
- Keywords
- Metabolic Diseases, Cardiovascular Diseases, Pulmonary, Diabetes, Computational Chemistry, Obesity.
- HQ
- South San Francisco, California
Structure Therapeutics Questions
Structure Therapeutics's website is https://structuretx.com/
Structure Therapeutics's LinkedIn profile is https://www.linkedin.com/company/structuretx
Structure Therapeutics has
175 employees.
View email and phone details for 175
employees at Structure Therapeutics.
Structure Therapeutics's industry is
Biotechnology Research
Structure Therapeutics's top competitors are
Montara Therapeutics, Inc.,
Maplight Therapeutics, Inc.,
Genesis Therapeutics,
Vilya,
Xaira Therapeutics,
Genista Biosciences,
Abdera Therapeutics,
Cargo Therapeutics,
Kyverna Therapeutics,
Editco Bio.
Structure Therapeutics's categories are Biotechnology Research
Structure Therapeutics's founding year is 2017
